Abstract
Nontraditional risk factors for cerebrovascular disease are rapidly emerging. The categories are expanding, and include those related to infection, inflammation, sleep disorders, hemostasis, nutrition, endocrine, and ones individual genotype. Many of the promising factors lack large randomized prospective population studies confirming direct cause and effect. However there have been strong evidence supporting increased stroke risk factor for infection, obstructive sleep disorders, the metabolic syndrome and impaired glucose tolerance in particular. Unique drug targets have already been identified in some of these emerging risk factors. The complexity of the pathophysiology of this disease remains a challenge. For example despite repeated evidence of estrogen-related neuroprotection, large populationbased studies in postmenopausal women receiving estrogen replacement did not demonstrate the expected neuroprotection. This suggests that aggressive research both at the basic science and transitional level needs to evolve, to ensure targeted successful stroke therapy. The advent of nanotechnology including the development of targeted therapeutic nanospheres, and of revolutionary molecular technology resulting in the synthesis of specific peptide mimetics, bodes well for the future development of cerebrovascular drug treatment.
Keywords: Cerebral ischemia, stroke, nontraditional, novel, risk factors, cerebrovascular, obstructive sleep disorder, metabolic syndrome, inflammation, infection
Current Drug Targets
Title: Emerging Risk Factors for Cerebrovascular Disease
Volume: 8 Issue: 7
Author(s): Nina J. Solenski
Affiliation:
Keywords: Cerebral ischemia, stroke, nontraditional, novel, risk factors, cerebrovascular, obstructive sleep disorder, metabolic syndrome, inflammation, infection
Abstract: Nontraditional risk factors for cerebrovascular disease are rapidly emerging. The categories are expanding, and include those related to infection, inflammation, sleep disorders, hemostasis, nutrition, endocrine, and ones individual genotype. Many of the promising factors lack large randomized prospective population studies confirming direct cause and effect. However there have been strong evidence supporting increased stroke risk factor for infection, obstructive sleep disorders, the metabolic syndrome and impaired glucose tolerance in particular. Unique drug targets have already been identified in some of these emerging risk factors. The complexity of the pathophysiology of this disease remains a challenge. For example despite repeated evidence of estrogen-related neuroprotection, large populationbased studies in postmenopausal women receiving estrogen replacement did not demonstrate the expected neuroprotection. This suggests that aggressive research both at the basic science and transitional level needs to evolve, to ensure targeted successful stroke therapy. The advent of nanotechnology including the development of targeted therapeutic nanospheres, and of revolutionary molecular technology resulting in the synthesis of specific peptide mimetics, bodes well for the future development of cerebrovascular drug treatment.
Export Options
About this article
Cite this article as:
Nina J. Solenski , Emerging Risk Factors for Cerebrovascular Disease, Current Drug Targets 2007; 8 (7) . https://dx.doi.org/10.2174/138945007781077364
| DOI https://dx.doi.org/10.2174/138945007781077364 |
Print ISSN 1389-4501 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Emerging Drug Targets and Revolutionary Therapeutic Approaches for Effective Anti-Cancer Intervention
Recent advancements in cancer research have significantly advanced our understanding of the intricate molecular mechanisms driving cancer progression, leading to the identification of new drug targets and therapeutic strategies. The elucidation of complex signaling pathways and genetic aberrations associated with tumorigenesis has provided valuable insights into potential targets for intervention. ...read more
Multitarget Agents For Complex Diseases
The basic principle of action of a drug is based on the model lock and key, where the highest possible affinity for a target results in no side effects. For many years, it was desirable‘one drug for one target for one disease’; however, the researchers observed that complex diseases are ...read more
Progress in Drug Delivery, Therapeutic Strategies, and Nursing Practices: Enhancing Diagnostics and Clinical Outcomes in Complex Diseases
The recent advancements in drug delivery systems, as well as therapeutics, have significantly improved therapy effectiveness, combined with better patient results, specifically for difficult disease management. The modern pharmaceutical research field makes drug targeting its main priority because this approach strengthens therapeutic agents' precision while improving their effectiveness. Multiple delivery ...read more
Recent Updates on the Molecular Targets of Chalcones
Chalcones are chemically alpha, beta-unsaturated ketones derived from the flavonoid family. The ease of synthesis and interactions with various molecular targets prompted greater attention in the field of medicinal chemistry. Recently, various aromatic or heteroaromatic derived chalcones showed good targets on neurological, cancer, diabetic, and inflammation, etc. The current thematic ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews Interaction of Anthocyanins with Drug-metabolizing and Antioxidant Enzymes
Current Medicinal Chemistry Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease
Current Pharmaceutical Design Anti-Inflammatory Therapy for Alzheimer’s Disease from Epidemiological Fact to New Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Systemic Hypertension in Patients with Aortic Stenosis: Clinical Implications and Principles of Pharmacological Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Treatment for Lysosomal Storage Disorders
Current Pharmaceutical Design Targeting Myocardial Metabolism for the Treatment of Stable Angina
Current Pharmaceutical Design Vitamin D and Stroke: Promise for Prevention and Better Outcome
Current Vascular Pharmacology Dietary Intake and Physical Activity in a Canadian Population Sample of Male Patients with HIV Infection and Metabolic Abnormalities
Current HIV Research Resveratrol: A Natural Polyphenol with Multiple Chemopreventive Properties (Review)
Current Drug Metabolism Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain
Current Drug Targets Impact of High Protein Intake on Viral Load and Hematological Parameters in HIV-infected Patients
Current HIV Research Modulation of Heart Rate by Acute or Chronic Aerobic Exercise. Potential Effects on Blood Pressure Control
Current Pharmaceutical Design Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?
Current Pharmaceutical Design Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy Experimental Antioxidant Biotherapy for Protection of the Vascular Wall by Modified Forms of Superoxide Dismutase and Catalase
Current Pharmaceutical Design RNA Interference and Potential Applications
Current Topics in Medicinal Chemistry From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug Candidates
Current Medicinal Chemistry Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure
Current Medicinal Chemistry Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy





